-+ 0.00%
-+ 0.00%
-+ 0.00%
Nippon Shinyaku's Jaypirca Wins Approval for First-Line Treatment of Chronic Lymphocytic Leukemia
Share
Listen to the news
Nippon Shinyaku's Jaypirca Wins Approval for First-Line Treatment of Chronic Lymphocytic Leukemia
  • Nippon Shinyaku secured expanded approval for Jaypirca 50 mg and 100 mg tablets as first-line treatment for previously untreated chronic lymphocytic leukemia.
  • Reported BRUIN-CLL-313 results showed pirtobrutinib helped patients live longer without disease progression than bendamustine with rituximab in a 282-patient Phase 3 trial.
  • Neutropenia was the most common adverse drug reaction with pirtobrutinib in both the BRUIN-CLL-313 and BRUIN-CLL-314 Phase 3 trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending